Cargando…

2036. Plasma (1→3)-β-D-Glucan Levels Correlate with Neurocognitive Functioning in HIV-Infected Adults

BACKGROUND: Although antiretroviral therapy (ART) has improved survival and morbidity, HIV-infected adults still have higher rates of non-AIDS disorders, such as neurocognitive impairment, than HIV-uninfected adults. (1–3)-b-D-Glucan (BDG) is a fungal cell wall component which serves as a plasma bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoenigl, Martin, Letendre, Scott, Finkelman, Malcolm, Gianella, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252470/
http://dx.doi.org/10.1093/ofid/ofy210.1692
_version_ 1783373272215191552
author Hoenigl, Martin
Letendre, Scott
Finkelman, Malcolm
Gianella, Sara
author_facet Hoenigl, Martin
Letendre, Scott
Finkelman, Malcolm
Gianella, Sara
author_sort Hoenigl, Martin
collection PubMed
description BACKGROUND: Although antiretroviral therapy (ART) has improved survival and morbidity, HIV-infected adults still have higher rates of non-AIDS disorders, such as neurocognitive impairment, than HIV-uninfected adults. (1–3)-b-D-Glucan (BDG) is a fungal cell wall component which serves as a plasma biomarker for fungal infection and—in the absence of fungal infections—for gut barrier integrity failure and microbial translocation. The objective of this study was to determine whether higher plasma and cerebrospinal fluid (CSF) levels of BDG are associated with neurocognitive impairment [evaluated by global deficit score (GDS)] in HIV-infected adults. METHODS: We measured levels of BDG in paired plasma and CSF samples, and compared levels with GDS, soluble urokinase plasminogen activator receptor (suPAR; a marker of monocyte activation and chronic inflammation that has previously been associated with non-AIDS disorders) and plasma CD4/CD8 ratio in a cohort of 61 HIV+ adults on suppressive ART. Study samples were collected as part of the prospective CHARTER study between 2005 and 2015 at the University of California San Diego and were stored at −80°C on the day of collection. BDG testing of blood plasma and CSF supernatant was performed at the Associates of Cape Cod, Inc., research laboratories using the Fungitell assay. RESULTS: Median plasma BDG level was 18 pg/mL (range: 2–60 pg/mL), median CSF BDG level was 20 pg/mL (range: 0–830 pg/mL). Higher levels of plasma BDG were associated with more severe cognitive impairment as measured by the GDS (Spearman r = 0.35; P = 0.006, Figure). Individuals with neurocognitive impairment (i.e., GDS > 0.5, n = 33) had higher plasma BDG levels compared with unimpaired individuals (P = 0.027). Plasma levels of BDG and suPAR correlated significantly (r = 0.31, P = 0.016), while all other correlations were nonsignificant (e.g., CSF BDG and GDS [r = 0.23], plasma suPAR and GDS [r = 0.19], CSF suPAR and GDS [r = −0.022], CD4/CD8 ratio and GDS [r = −0.028]). CONCLUSION: Elevated plasma levels of BDG may be an indicator of gut barrier integrity failure and an independent biomarker associated with neurocognitive functioning in HIV+ adults on suppressive ART. [Image: see text] DISCLOSURES: M. Finkelman, Associated of Cape Cod: Employee, Salary.
format Online
Article
Text
id pubmed-6252470
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62524702018-11-28 2036. Plasma (1→3)-β-D-Glucan Levels Correlate with Neurocognitive Functioning in HIV-Infected Adults Hoenigl, Martin Letendre, Scott Finkelman, Malcolm Gianella, Sara Open Forum Infect Dis Abstracts BACKGROUND: Although antiretroviral therapy (ART) has improved survival and morbidity, HIV-infected adults still have higher rates of non-AIDS disorders, such as neurocognitive impairment, than HIV-uninfected adults. (1–3)-b-D-Glucan (BDG) is a fungal cell wall component which serves as a plasma biomarker for fungal infection and—in the absence of fungal infections—for gut barrier integrity failure and microbial translocation. The objective of this study was to determine whether higher plasma and cerebrospinal fluid (CSF) levels of BDG are associated with neurocognitive impairment [evaluated by global deficit score (GDS)] in HIV-infected adults. METHODS: We measured levels of BDG in paired plasma and CSF samples, and compared levels with GDS, soluble urokinase plasminogen activator receptor (suPAR; a marker of monocyte activation and chronic inflammation that has previously been associated with non-AIDS disorders) and plasma CD4/CD8 ratio in a cohort of 61 HIV+ adults on suppressive ART. Study samples were collected as part of the prospective CHARTER study between 2005 and 2015 at the University of California San Diego and were stored at −80°C on the day of collection. BDG testing of blood plasma and CSF supernatant was performed at the Associates of Cape Cod, Inc., research laboratories using the Fungitell assay. RESULTS: Median plasma BDG level was 18 pg/mL (range: 2–60 pg/mL), median CSF BDG level was 20 pg/mL (range: 0–830 pg/mL). Higher levels of plasma BDG were associated with more severe cognitive impairment as measured by the GDS (Spearman r = 0.35; P = 0.006, Figure). Individuals with neurocognitive impairment (i.e., GDS > 0.5, n = 33) had higher plasma BDG levels compared with unimpaired individuals (P = 0.027). Plasma levels of BDG and suPAR correlated significantly (r = 0.31, P = 0.016), while all other correlations were nonsignificant (e.g., CSF BDG and GDS [r = 0.23], plasma suPAR and GDS [r = 0.19], CSF suPAR and GDS [r = −0.022], CD4/CD8 ratio and GDS [r = −0.028]). CONCLUSION: Elevated plasma levels of BDG may be an indicator of gut barrier integrity failure and an independent biomarker associated with neurocognitive functioning in HIV+ adults on suppressive ART. [Image: see text] DISCLOSURES: M. Finkelman, Associated of Cape Cod: Employee, Salary. Oxford University Press 2018-11-26 /pmc/articles/PMC6252470/ http://dx.doi.org/10.1093/ofid/ofy210.1692 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Hoenigl, Martin
Letendre, Scott
Finkelman, Malcolm
Gianella, Sara
2036. Plasma (1→3)-β-D-Glucan Levels Correlate with Neurocognitive Functioning in HIV-Infected Adults
title 2036. Plasma (1→3)-β-D-Glucan Levels Correlate with Neurocognitive Functioning in HIV-Infected Adults
title_full 2036. Plasma (1→3)-β-D-Glucan Levels Correlate with Neurocognitive Functioning in HIV-Infected Adults
title_fullStr 2036. Plasma (1→3)-β-D-Glucan Levels Correlate with Neurocognitive Functioning in HIV-Infected Adults
title_full_unstemmed 2036. Plasma (1→3)-β-D-Glucan Levels Correlate with Neurocognitive Functioning in HIV-Infected Adults
title_short 2036. Plasma (1→3)-β-D-Glucan Levels Correlate with Neurocognitive Functioning in HIV-Infected Adults
title_sort 2036. plasma (1→3)-β-d-glucan levels correlate with neurocognitive functioning in hiv-infected adults
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252470/
http://dx.doi.org/10.1093/ofid/ofy210.1692
work_keys_str_mv AT hoeniglmartin 2036plasma13bdglucanlevelscorrelatewithneurocognitivefunctioninginhivinfectedadults
AT letendrescott 2036plasma13bdglucanlevelscorrelatewithneurocognitivefunctioninginhivinfectedadults
AT finkelmanmalcolm 2036plasma13bdglucanlevelscorrelatewithneurocognitivefunctioninginhivinfectedadults
AT gianellasara 2036plasma13bdglucanlevelscorrelatewithneurocognitivefunctioninginhivinfectedadults